PMID- 29339445
OWN - NLM
STAT- MEDLINE
DCOM- 20190409
LR  - 20190418
IS  - 1540-9538 (Electronic)
IS  - 0022-1007 (Print)
IS  - 0022-1007 (Linking)
VI  - 215
IP  - 2
DP  - 2018 Feb 5
TI  - Bile acids in glucose metabolism in health and disease.
PG  - 383-396
LID - 10.1084/jem.20171965 [doi]
AB  - Bile acids (BAs) are cholesterol-derived metabolites that facilitate the 
      intestinal absorption and transport of dietary lipids. Recently, BAs also emerged 
      as pivotal signaling molecules controlling glucose, lipid, and energy metabolism 
      by binding to the nuclear hormone farnesoid X receptor (FXR) and Takeda G protein 
      receptor 5 (TGR5) in multiple organs, leading to regulation of intestinal 
      incretin secretion, hepatic gluconeogenesis, glycogen synthesis, energy 
      expenditure, inflammation, and gut microbiome configuration. Alterations in BA 
      metabolism and signaling are associated with obesity and type 2 diabetes mellitus 
      (T2DM), whereas treatment of T2DM patients with BA sequestrants, or bariatric 
      surgery in morbidly obese patients, results in a significant improvement in 
      glycemic response that is associated with changes in the BA profile and 
      signaling. Herein, we review the roles of BAs in glucose metabolism in health and 
      disease; highlight the limitations, unknowns, and challenges in understanding the 
      impact of BAs on the glycemic response; and discuss how this knowledge may be 
      harnessed to develop innovative therapeutic approaches for the treatment of 
      hyperglycemia and diabetes.
CI  - (c) 2018 Shapiro et al.
FAU - Shapiro, Hagit
AU  - Shapiro H
AD  - Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
FAU - Kolodziejczyk, Aleksandra A
AU  - Kolodziejczyk AA
AUID- ORCID: 0000-0002-2903-8884
AD  - Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
FAU - Halstuch, Daniel
AU  - Halstuch D
AUID- ORCID: 0000-0002-6331-5056
AD  - Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
FAU - Elinav, Eran
AU  - Elinav E
AD  - Department of Immunology, Weizmann Institute of Science, Rehovot, Israel 
      eran.elinav@weizmann.ac.il.
LA  - eng
GR  - HHMI/Howard Hughes Medical Institute/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180116
PL  - United States
TA  - J Exp Med
JT  - The Journal of experimental medicine
JID - 2985109R
RN  - 0 (Bile Acids and Salts)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Receptors, Cytoplasmic and Nuclear)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - 0C5V0MRU6P (farnesoid X-activated receptor)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - Bile Acids and Salts/*metabolism
MH  - Diabetes Mellitus/etiology/metabolism
MH  - Gastrointestinal Microbiome
MH  - Glucose/*metabolism
MH  - Humans
MH  - Inflammation Mediators/metabolism
MH  - Lipid Metabolism
MH  - Receptors, Cytoplasmic and Nuclear/metabolism
MH  - Receptors, G-Protein-Coupled/metabolism
MH  - Signal Transduction
PMC - PMC5789421
EDAT- 2018/01/18 06:00
MHDA- 2019/04/10 06:00
PMCR- 2018/08/05
CRDT- 2018/01/18 06:00
PHST- 2017/10/30 00:00 [received]
PHST- 2017/12/11 00:00 [revised]
PHST- 2017/12/19 00:00 [accepted]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2019/04/10 06:00 [medline]
PHST- 2018/01/18 06:00 [entrez]
PHST- 2018/08/05 00:00 [pmc-release]
AID - jem.20171965 [pii]
AID - 20171965 [pii]
AID - 10.1084/jem.20171965 [doi]
PST - ppublish
SO  - J Exp Med. 2018 Feb 5;215(2):383-396. doi: 10.1084/jem.20171965. Epub 2018 Jan 
      16.